Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
NCT05726864 · View on ClinicalTrials.gov ↗
Study Summary
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides 7P\]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.
Conditions Studied
Interventions
- DRUG ELI-002 7P
Study Locations (20)
California
- City of Hope — Duarte
- Cedars-Sinai Medical Center — Los Angeles
- University of California Los Angeles — Los Angeles
- University of California, Irvine — Orange
Florida
- University of Miami — Coral Gables
- University of Florida Health Cancer Center — Gainesville
- Mayo Clinic Comprehensive Cancer Center — Jacksonville
- Moffitt Cancer Center — Tampa
Arizona
- Banner MD Anderson Cancer Center — Gilbert
- Mayo Clinic Comprehensive Cancer Center — Phoenix
Massachusetts
- Massachusetts General Hospital — Boston
- Dana Farber Cancer Institute — Boston
New York
- Northwell Health — Lake Success
- Memorial Sloan Kettering Cancer Center — New York
Colorado
- University of Colorado Hospital-Anschutz Cancer Pavillion — Aurora
Georgia
- Emory Winship Cancer Institute — Atlanta
Iowa
- University of Iowa — Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2023-04-14 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05726864
The ClinicalTrials.gov registry entry for NCT05726864 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elicio Therapeutics, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention — of which ELI-002 7P is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05726864 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05726864 about?
NCT05726864 is a clinical study titled "A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors". This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides 7P\]) as adjuvant treatment in subjects with solid tumors with mu...
What is the current status of trial NCT05726864?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 158 participants. The study started on 2023-04-14. Estimated completion is 2026-11.
What conditions does trial NCT05726864 study?
This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, KRAS G12C, KRAS G12D, KRAS G12A. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05726864?
The interventions under investigation include: ELI-002 7P (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05726864?
This trial is sponsored by Elicio Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05726864 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.